PROGNOSTIC FACTORS FOR RESPONSE AND SURVIVAL WITH ALPHA-INTERFERON (IFN-A) THERAPY IN EARLY CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML)

被引：0
|
作者：
KANTARJIAN, H [1 ]
SMITH, T [1 ]
OBRIEN, S [1 ]
ROBERTSON, L [1 ]
KOLLER, C [1 ]
BERAN, M [1 ]
KEATING, M [1 ]
TALPAZ, M [1 ]
机构：
[1] MD ANDERSON CANC CTR,HOUSTON,TX
来源：
BLOOD | 1993年 / 82卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A378 / A378
页数：1
相关论文
共 50 条
  • [41] Interferon therapy in chronic myelogenous leukemia
    Guilhot, F
    Roy, L
    Guilhot, J
    Millot, F
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2004, 18 (03) : 585 - +
  • [42] Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia
    Sacchi, S
    Kantarjian, HM
    Smith, TL
    O'Brien, S
    Pierce, S
    Kornblau, S
    Beran, M
    Keating, MJ
    Talpaz, M
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (03) : 882 - 889
  • [43] FACTORS THAT PREDICT A FAVORABLE RESPONSE TO ALPHA-INTERFERON (IFN) IN PATIENTS WITH CHRONIC HEPATITIS-C
    RABINOVITZ, M
    BLOCK, G
    FINKELSTEIN, S
    HEPATOLOGY, 1994, 20 (04) : A158 - A158
  • [44] Simultaneous homoharringtonine (HHT) and interferon alpha (IFN-α) therapy is an effective regimen in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML).
    O'Brien, S
    Kantarjian, H
    Cortes, J
    Giles, FJ
    Beran, M
    Rios, MB
    Mallard, S
    Cheson, B
    Murgo, A
    Talpaz, M
    BLOOD, 1998, 92 (10) : 251A - 251A
  • [45] Absence of influence of prior interferon alfa (IFN alpha) therapy on the outcome of allogeneic bone marrow transplantation (BMT) for chronic myelogenous leukemia (CML).
    Tomas, IF
    Steegman, IL
    Requena, MI
    Soria, VGG
    FernandezRanada, IM
    BLOOD, 1995, 86 (10) : 3859 - 3859
  • [46] USE OF ALPHA-INTERFERON FOR THE TREATMENT OF RELAPSE OF CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
    HIGANO, CS
    RASKIND, WH
    SINGER, JW
    BLOOD, 1992, 80 (06) : 1437 - 1442
  • [47] RANDOMIZED COMPARISON OF INTERFERON-ALPHA WITH BUSULFAN AND HYDROXYUREA IN CHRONIC MYELOGENOUS LEUKEMIA (CML)
    HEHLMANN, R
    HEIMPEL, H
    HASFORD, J
    KOLB, HJ
    PRALLE, H
    HOSSFELD, DK
    QUEISSER, W
    LOFFLER, H
    HOCHHAUS, A
    HEINZE, B
    ANSARI, H
    BLOOD, 1994, 84 (10) : A382 - A382
  • [48] Interferon (IFN)-based combination chemotherapy in chronic myelogenous leukemia (CML): Increasing dose intensity improves response.
    Venugopal, P
    Gupta-Burt, S
    Slivinik, D
    Adler, S
    Gregory, SA
    Jajeh, A
    Hall, T
    Preisler, HD
    BLOOD, 1998, 92 (10) : 250B - 250B
  • [49] Glomerulopathy (GP) during interferon alpha therapy (IFN alpha) for chronic myelogenous leukaemia
    Pulik, M
    MoulonguetDoleris, L
    Nochy, D
    Lionnet, F
    Genet, P
    Petitdidier, C
    Touahri, T
    Jary, L
    Fourcade, C
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 1045 - 1045
  • [50] Impact of interferon-αtherapy duration and chronic myelogenous leukemia (CML) history on Glivec ® (STI 571) response in interferon-resistant or intolerant CML patients in chronic and in accelerated phase.
    Michallet, M
    Le, QH
    Mates, M
    Berthaud, P
    Troncy, J
    Fiere, D
    Nicolini, F
    BLOOD, 2001, 98 (11) : 263B - 263B
12345